Thermo Fisher Announce Owlstone Medical Collaboration
Thermo Fisher Scientific has announced a collaboration with Owlstone Medical to advance the early diagnosis of cancer and other diseases utilizing novel biomarkers and non-invasive breath sampling.
Thermo Fisher Scientific has announced a collaboration with Owlstone Medical to advance the early diagnosis of cancer and other diseases utilizing novel biomarkers and non-invasive breath sampling.
“There is a growing need for non-invasive diagnostic solutions to support early disease detection, patient treatment and increase remission rates,” said Morten Bern, director of marketing, gas chromatography, Thermo Fisher Scientific.
The collaboration will see Orbitrap gas chromatography–mass spectrometry (GC–MS) instrumentation integrated with Owlstone Medical’s Breath Biopsy platform allowing the detection of new biomarkers via a validated discovery and routine analysis project.
“With an installed base of GC Orbitrap systems, our collaboration with Thermo Fisher Scientific represents an exciting opportunity for cross-promotion of the platform and technique, by which the benefits of breath biopsy can be broadly realized,” said Billy Boyle, co-founder and chief executive officer at Owlstone Medical.
For more information, please visit: www.thermofisher.com
